NRL-1049
Product Specifications
UNSPSC Description
NRL-1049 (BA-1049) is a ROCK2 selective inhibitor (IC50: 0.59 µM and 26 µM for ROCK2 and ROCK1 respectively). NRL-1049 reduces Lysophosphatidic acid induced ROCK activation in endothelial cells. NRL-1049 reduces lesion volume and hemorrhagic transformation in a mouse model of cavernous angiomas. NRL-1049 also preserves the BBB and suppresses seizures after brain injury, and inhibits hemorrhagic transformation after ischemic stroke in mice[1].
Target Antigen
ROCK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage;Cytoskeleton;Stem Cell/Wnt;TGF-beta/Smad
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/nrl-1049.html
Smiles
C[C@H](C1CCN(CC1)S(=O)(C2=C3C=CN=CC3=CC=C2)=O)N
Molecular Weight
319.42
References & Citations
[1]Mulder IA, et al. The novel ROCK2 selective inhibitor NRL-1049 preserves the blood-brain barrier after acute injury. J Cereb Blood Flow Metab. 2024 Jun 4:271678X241238845.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-162596/NRL-1049-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-162596/
Clinical Information
No Development Reported
CAS Number
1973494-16-4
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
LS341405 100 µg
Ankyrin repeat domain containing protein 33 (ANKRD33) (NM_182608) Human Over-expression Lysate
Ask
View Details ![Rabbit Polyclonal CDC42EP2 Antibody [mFluor Violet 450 SE]](https://cdn.genprice.uk/genprice/genprice5.png)